Form 8-K
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 16, 2011

BIOLASE TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)

         
Delaware   000-19627   87-0442441
(State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)
     
4 Cromwell
Irvine, California
  92618
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (949) 361-1200

 
Not Applicable
(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

1

 

Item 7.01 Regulation FD Disclosure.

On March 16, 2011, Federico Pignatelli, Chairman and Chief Executive Officer of Biolase Technology, Inc. (the “Company”) will deliver a presentation at the Roth 23rd Annual Growth Stock Conference that will include a written communication comprised of slides. The slides from the presentation are attached hereto as Exhibit 99.1, and are hereby incorporated by reference.

A copy of the slides will be available for viewing and download at http://www.biolase.com/investors for a period of 30 days.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Presentation material from the Roth 23rd Annual Growth Stock Conference, dated March 16, 2011.

2

 

2

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOLASE TECHNOLOGY, INC.

Date: March 16, 2011

By: /s/ Federico Pignatelli                                 
Federico Pignatelli
Chairman and Chief Executive Officer

 

3

3

 

Exhibit Index

     
 
    
Exhibit No. 
   Description
99.1
  Presentation material from the Roth 23rd Annual Growth Stock Conference, dated March 16, 2011.

 

4

4